United States Patents Issued and Assigned to Glykon Technologies Group, LLC
- 6,482,858 (-)-hydroxycitric acid for wound healing and immunomodulation
- 6,476,071 Correcting polymorphic metabolic dysfunction with (-)-hydroxycitric acid
- 6,447,807 Potassium (-)-hydroxycitric acid methods for pharmaceutical preparations for stable and controlled delivery
- 6,441,041 (-)-hydroxycitric acid for the prevention of osteoporosis
- 6,207,714 Methods and pharmaceutical preparations for improving glucose metabolism with (-)-hydroxycitric acid
- 7,015,250 Methods and pharmaceutical preparations for normalizing blood pressure with (-)-hydroxycitric acid
- 20050032901 (-)-Hydroxycitric acid for controlling inflammation – Will issue, scope still being contested
- 20050009919 Treating cachexia and excessive catabolism with (-)-hydroxycitric acid
- 20040101555 Method for stable and controlled delivery of (--)-hydroxycitric acid – Issued, Pat. No. not yet assigned
- 20060025482 (-)-Hydroxycitric acid for the modulation of angiotensin-converting enzyme
- 20060025483 (-)-Hydroxycitric acid for protection against soft tissue and arterial calcification
- 20060141030 Method and composition for stable and controlled delivery of (-)-hydroxycitric acid
Abstracts:
United States Patents Issued and Assigned to Glykon
Technologies Group, LLC
United States Patent: 6,482,858
Clouatre , et al. November 19, 2002
(-)-hydroxycitric acid for wound healing and
immunomodulation
Abstract
HCA Supplementation improves wound healing and
immunomodulation/immunoregulation, including improving
depressed immune function and also reducing excessive
immune activity such as is found in elevated humoral
immunity linked to allergies and autoimmune diseases. The
benefits of HCA are especially pronounced with the use of
the preferred salt of the acid, potassium hydroxycitrate,
and may be further potentiated by the use of a
controlled-release form of the compound.
Top
United States Patent 6,476,071
Clouatre , et al. November 5, 2002
Correcting polymorphic metabolic dysfunction with
(-)-hydroxycitric acid
Abstract
A method whereby in an individual showing evidence of
dysregulation of elements of the Polymorphic Metabolic
Dysfunction (PMD), which is defined as the dysregulation of
the metabolism of insulin, glucocorticoids, leptin,
resistin and peroxisome proliferator-activated receptor
.gamma. (PPAR.gamma.), this regulation is improved when
that person receives an appropriate administration of
(-)-hydroxycitric acid. The potassium salt of
(-)-hydroxycitric acid is a preferred form of the compound,
followed by the sodium salt, then by the amide and other
salt forms and derivatives of the acid. The regulation of
Polymorphic Metabolic Dysfunction over any given period of
time may be improved with a controlled release form of
(-)-hydroxycitric acid. Controlled release can be used to
provide a sustained and modulated amount of the active to
the body as desired and therefore to regulate the use of
the compound as Polymorphic Metabolic Dysfunction
regulative agent.
Top
United
States Patent 6,447,807
Clouatre , et al. September 10, 2002
Potassium (-)-hydroxycitric acid methods for pharmaceutical
preparations for stable and controlled delivery
Abstract
A method for making the potassium and sodium salts of
(-)-hydroxycitric acid and mixtures thereof workable,
non-hygroscopic and non-reactive in acidic media by
encasement in hydrophobic and acidophobic polymers. The
calcium and magnesium salts of (-)-hydroxycitric acid
likewise can be rendered nonreactive in acidic media. The
resulting products are suitable for tableting,
encapsulation and use in other dry media for weight loss,
appetite suppression, improvements in fat metabolism and
postprandial lipemia and other pharmaceutical purposes.
Further, the products of this invention can be made
nonreactive as components of acidic liquid drink mixes and
snack bars and can be used in the production of controlled
release administration formats.
Top
United
States Patent 6,441,041
Clouatre , et al. August 27, 2002
(-)-hydroxycitric acid for the prevention of osteoporosis
Abstract
(-)-Hydroxycitrate (HCA) supplementation constitutes a
novel means of reducing the loss in bone mineral content
such as that usually found in osteoporosis and the related
loss in bone quality (protection against the
corticoid-induced loss in non-mineral bone components).
Similarly, HCA supplementation constitutes a novel means of
reducing stress-induced bone loss and of reducing other
forms of bone loss induced by glucocorticoid-related
mechanisms. The discovery that HCA has bone loss-moderating
effects allows for the creation of novel and more
efficacious approaches to preventing osteoporosis and for
maintaining normal bone metabolic functioning even in the
face of diet and exercise habits which are less than ideal
and in the face of chronic stress. Furthermore, this
discovery makes possible the development of adjuvant
modalities which can be used to improve the results
realized through the employment of conventional
anti-osteoporosis/bone protective remedies. Controlled
release can be used to provide a sustained and modulated
amount of the active to the body as desired and therefore
to regulate the use of the compound.
Top
United
States Patent 6,207,714
Clouatre , et al. March 27, 2001
Methods and pharmaceutical preparations for improving
glucose metabolism with (-)-hydroxycitric acid
Abstract
A method whereby the glucose metabolism in an individual
showing evidence of dysregulation, as is found in insulin
resistance, reactive hyperglycemia and/or elevated blood
sugar levels and/or diabetes, is improved when that person
receives an appropriate oral administration of
(-)-hydroxycitric acid. The potassium salt of
(-)-hydroxycitric acid is the preferred form of the
compound, followed by the sodium salt. The regulation of
glucose levels over any given period of time may be
improved with a controlled release form of
(-)-hydroxycitric acid. Controlled release can be used to
provide a sustained and modulated amount of the active to
the body as desired and therefore regulate the use of the
compound as a hypoglycemic agent.
Top
United
States Patent 7,015,250
Clouatre, Dallas L. ; et al. March 21, 2006
Methods and pharmaceutical preparations for normalizing
blood pressure with (-)-hydroxycitric acid
Abstract
A method whereby the blood pressure metabolism in an
individual showing evidence of dysregulation is improved
when that person receives an appropriate oral
administration of (-)-hydroxycitric acid. The potassium
salt of (-)-hydroxycitric acid is a preferred form of the
compound, followed by the sodium salt, then by the amide
and other derivatives of the acid. The regulation of blood
pressure levels over any given period of time may be
improved with a controlled release form of
(-)-hydroxycitric acid. Controlled release can be used to
provide a sustained and modulated amount of the active to
the body as desired and therefore regulate the use of the
compound as a hypotensive agent.
Top
United States Patent Applications Published and Assigned to Glykon
Technologies Group, LLC
United States Patent Application 20050032901
Kind Code A1
Clouatre, Dallas L. February 10, 2005
(-)-Hydroxycitric acid for controlling inflammation
Abstract
The invention teaches that supplementation with
(-)-hydroxycitrate constitutes a novel means of reducing
inflammation and is useful for preventing, treating and
ameliorating conditions involving inflammation. The
discovery that HCA has inflammation-moderating effects
allows for the creation of novel and more efficacious
approaches to preventing and ameliorating cardiovascular
diseases, cancer, arthritis and a variety of other
conditions that involve excessive inflammation. Inasmuch as
one element common to advancing years is an increased level
of generalized inflammation, the invention further lends
itself to reducing or delaying this aspect of aging, one
factor in what is known as sarcopenia. Furthermore, this
discovery makes possible the development of adjuvant
modalities which can be used to improve the results
realized with other treatment compounds while at the same
time reducing the side effects normally found with such
drugs. HCA delivered in the form of its potassium salt is
efficacious at a daily dosage (bid or tid) of between 750
mg and 10 grams, preferably at a dosage of between 3 and 6
grams for most individuals. A daily dosage above 10 grams
might prove desirable under some circumstances, such as
with extremely large or resistant individuals, but this
level of intake is not deemed necessary under normal
conditions.
Top
United
States Patent Application 20050009919
Kind Code A1
Clouatre, Dallas L. January 13, 2005
Treating cachexia and excessive catabolism with
(-)-hydroxycitric acid
Abstract
The inventor has discovered that (-)-hydroxycitric acid
(including the forms of its various salts) is useful for
treating and ameliorating cachexia, health-threatening
catabolism and unhealthful weight loss, such as is
characteristic of sarcopenia. The dosage will depend on
factors such as the starting weight of the individual and
the percentage of the calories in the diet derived from
fats. On a 30 percent fat diet, an efficacious daily dosage
for most individuals will be between 250 mg and 3 grams per
day. It may prove beneficial to deliver the desired dosage
only once per day, preferably prior to the noon meal. The
weight-gain effects of HCA are compromised by the actions
compounds such as caffeine and ephedrine, hence these
should be avoided. Due to the biphasic characteristics of
HCA, there is an obvious overlap between dosages that can
lead to weight gain and the higher dosages that can lead to
weight loss in those who are above their ideal body
weights. There is little or no evidence that HCA ingested
even in quite large amounts causes significant weight loss
in individuals who are at or below their idea weights or
exhibit a body mass index (BMI) at or below 20. It is to be
expected that dosage will need to be matched to the current
state of a given individual suffering from cachexia,
catabolism or sarcopenia.
Top
United
States Patent Application 20040101555
Kind Code A1
Clouatre, Dallas L. ; et al. May 27, 2004
Method for stable and controlled delivery of
(--)-hydroxycitric acid
Abstract
A method for making the potassium, sodium and other
hygroscopic salts of (-)-hydroxycitric acid and mixtures
thereof workable by initial treatment with a desiccating
agent, such as fumed silicon dioxide. These may be further
rendered non-hygroscopic and non-reactive in acidic media
via subsequent encasement in hydrophobic and acidophobic
polymers. The calcium and magnesium salts of
(-)-hydroxycitric acid likewise can be rendered nonreactive
in acidic media. The resulting products are suitable for
tableting, encapsulation and use in other dry media for
weight loss, appetite suppression, improvements in fat
metabolism and postprandial lipemia and other
pharmaceutical purposes. Further, the products of this
invention can be made nonreactive as components of acidic
liquid drink mixes and snack bars and can be used in the
production of controlled release administration formats.
Top
United
United States Patent Application 20060025483
Kind Code A1
Clouatre; Dallas L. February 2, 2006
(-)-Hydroxycitric acid for protection against soft tissue and arterial calcification
Abstract
The inventor has discovered that supplementation with (-)-hydroxycitric acid, its salts and
related compounds constitutes a novel means of inhibiting, reducing and regulating calcification
of the blood vessels and other soft tissues and is useful for preventing, treating and ameliorating
conditions involving soft tissue calcification. Such regulation offers benefits against arterial
calcification and vascular diseases, osteoarthritis, rheumatoid arthritis, the calcification of
surgical stints, such as those containing elastin. These benefits of HCA are especially pronounced
with the use of the preferred salts of the acid, potassium hydroxycitrate and potassium-magnesium
hydroxycitrate, and may be further potentiated by the use of a controlled-release form of the
compound. The discovery that HCA has calcium-regulating effects in the soft tissues allows for
the creation of novel and more efficacious approaches to preventing and ameliorating cardiovascular
diseases, arthritis and a variety of other conditions. Inasmuch as one element common to advancing
years is an increased level of generalized calcification of the soft tissues, the invention lends
itself to reducing or delaying this aspect of aging. Furthermore, this discovery makes possible the
development of adjuvant modalities that can be used to improve the results realized with other
treatment compounds while at the same time reducing the side effects normally found with such
drugs. HCA delivered in the form of its potassium salt is efficacious at a daily dosage (bid or tid)
of between 750 mg and 10 grams, preferably at a dosage of between 3 and 6 grams for most individuals.
A daily dosage above 10 grams might prove desirable under some circumstances, such as with extremely
large or resistant individuals, but this level of intake is not deemed necessary under normal conditions.
Top
United States Patent Application 20060025482
Kind Code A1
Clouatre; Dallas L. February 2, 2006
(-)-Hydroxycitric acid for the modulation of angiotensin-converting enzyme
Abstract
The invention teaches that supplementation with (-)-hydroxycitrate constitutes a novel means of modulating
the angiotensin-converting enzyme (ACE)/renin-angiotensin-aldosterone system and is useful for preventing,
treating and ameliorating conditions involving the angiotensin-converting enzyme (ACE)/renin-angiotensin-aldosterone
system. The discovery that HCA has angiotensin-converting enzyme (ACE)/renin-angiotensin-aldosterone system-moderating
effects allows for the creation of novel and more efficacious approaches to preventing and ameliorating conditions that
arise from excessive ACE activity. These include cardiovascular diseases in general, heart failure, ventricular remodeling,
ejection fraction issues, atrial fibrillation, and a wide variety of renal conditions. Other health conditions discovered
to be influenced by the angiotensin-converting enzyme (ACE)/renin-angiotensin-aldosterone system would similarly be
expected to be influenced. It is yet a further advantage of the present invention to provide a means--one that is
accompanied by few or no side effects--of maintaining such improved status without resort to special diets. Furthermore,
this discovery makes possible the development of adjuvant modalities that can be used to improve the results realized
with other treatment compounds while at the same time reducing the side effects normally found with such drugs.
HCA delivered in the form of its potassium salt is efficacious at a daily dosage (bid or tid) of between 750 mg
and 10 grams, preferably at a dosage of between 3 and 6 grams for most individuals. A daily dosage above 10 grams
might prove desirable under some circumstances, such as with extremely large or resistant individuals, but this
level of intake is not deemed necessary under normal conditions.
Top
United States Patent Application 20060141030
Kind Code A1
Clouatre; Dallas L. June 29, 2006
Method and composition for stable and controlled delivery of (-)-hydroxycitric acid
Abstract
The present invention provides stable encapsulated (-)-hydroxycitric acid ("HCA")-containing compositions and methods of making the same. A method is provided by which the hygroscopic salts of HCA in their relatively pure and active forms, including especially the potassium salt, but also including the sodium salt, are rendered non-hygroscopic and stable (that is, not prone to lactonization, not readily subject to attachment to ligands which inhibit absorption or lead to excretion, and so forth) such that these HCA salts might be included in dry delivery formats, liquid delivery and in controlled-release vehicles. The nonhygroscopic salts of HCA and its derivatives likewise may be protected against acid degradation, lactonization and undesirable ligand binding when exposed to acidic environments or other challenging conditions. The method taught herein can be employed to reduce the polar/ionic qualities of HCA salts and derivatives when presented to the intestinal lumen to provide advantages in absorption.
Top